Autopsy report · NCT03623776

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

“No patients enrolled.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Sun Yat-sen University

Sponsor type

University, hospital or other

Conditions

Efficacy and Safety

Interventions

JS001; Pemetrexed; Carboplatin; Thoracic Surgery

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients
  “No patients were enrolled.” (97% match in meaning)
• Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
  “no patient enrolled.” (96% match in meaning)
• Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
  “No eligible patients were enrolled.” (95% match in meaning)
• Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain
  “No patients enrolled in the study.” (94% match in meaning)
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
  “No eligible patient was enrolled.” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.